TVM Capital Life Science Invests in Kaneq Bioscience
strong>TVM Life Science Ventures VII has invested an undisclosed amount of money into Montréal-based Kaneq Bioscience Ltd. Kaneq is a biotechnology company focused on developing treatments for type 2 diabetes, and a spin out of Kaneq Pharma Inc. TVM Life Science Ventures VII, managed by TVM Capital Life Science, a venture capital firm with offices in Montréal, Munich and Boston, was closed at C$150 million in May, 2012.
22 January 2013•3 mins read
